Benjamin Lockshin

Dec 1, 2023 | dermatologytimes.com | Benjamin Lockshin

Panelists:Benjamin Lockshin, MD, FAADDermAssociatesRockville, MarylandProgram Description:An expert in dermatology provides insights from a case-based roundtable conversation, discussing the management vitiligo across diverse age groups and skin types. The discussion centers on understanding the challenges posed by vitiligo, addressing its impact on patients' well-being.

Dec 1, 2023 | hcplive.com | Bruce E. Strober |Benjamin Lockshin |Jennifer Soung

Bruce Strober, MD, PhD, FAAD: Ben, what are some of the pipeline therapeutics, future developments that you’re excited about with regard to psoriasis? Benjamin Lockshin, MD, FAAD: If you look at this space in terms of the treatment options, you’d think that we’re close to the goal line using a football analogy or that we’re in the red zone. I think we’re somewhere between the 50-yard line and approaching the red zone in terms of therapeutics.

Dec 1, 2023 | hcplive.com | Bruce E. Strober |Benjamin Lockshin |Jennifer Soung

Bruce Strober, MD, PhD, FAAD: Ben, can you share with me an anecdotal case of success that involves an IL-23 inhibitor, one that really was impactful for you? Benjamin Lockshin, MD, FAAD: There’s a couple situations, and I think one of the most remarkable stories is the patient who’s failed a number of treatments and then finally goes on a [IL-]23 and they’re clear again.

Dec 1, 2023 | hcplive.com | Bruce E. Strober |Benjamin Lockshin |Jennifer Soung

December 1, 2023Benjamin Lockshin, MD, FAAD, comments on the higher efficacy and reliability of recent IL-17 and IL-23 inhibitors and how these factors into treatment selection for patients with plaque psoriasis. Bruce Strober, MD, PhD, FAAD: So, Ben, this is a tougher question. How do you go about selecting among the various IL-23 inhibitors we have at our disposal? Benjamin Lockshin, MD, FAAD: That’s a challenging question. I think we are fortunate to have 3 very good options.

Nov 24, 2023 | hcplive.com | Bruce E. Strober |Benjamin Lockshin |Jennifer Soung

Bruce Strober, MD, PhD, FAAD: Jennifer, is there a paradigm shift occurring right now that you can foresee that defines how we approach psoriasis in 2023 moving into 2024 or from the way we did in 2015 to [20]18? Jennifer Soung, MD: I always tell my residents I don’t use biologics in the order that they were FDA approved. We see a lot of times [that] step therapy will tell us to use [biologics] in that order, and so our newer biologics, [such as] the [IL-]23s, are my first line.